The company recently expanded its pipeline by acquiring DMX-200 for kidney disease.
: Noted for its inhaled therapy for pulmonary arterial hypertension and its recent pursuit of FDA pediatric approval.
Recent Phase 1b study results for its Crohn's disease treatment showed a favorable safety profile with no serious adverse events. : best biotech stocks to buy under $10
It was also recognized as a top stock for day trading due to high relative volume. Value-Oriented Biotech Picks
Consistently featured in lists of best biotechs under $10 and is noted for its Cancer BioShield platform targeting lymphopenia. The company recently expanded its pipeline by acquiring
The primary catalyst is upcoming clinical data for ulcerative colitis, expected in the second half of 2027.
Identified as a top pick for its focus on like Fabry and Pompe disease. : It was also recognized as a top
AI responses may include mistakes. For financial advice, consult a professional. Learn more